Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | EVP & Chief Legal Officer | September 10, 2026 | September 14, 2026 |
| TELEFLEX INCTFX · Entity 3798 | Director | May 15, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jazz Pharmaceuticals plc
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 47,671 |
Reported balance
After 2026-09-10 transaction · row 1
1 source rowRow 1 · 2026-09-10 · Sale · Disposed 1,200 · Balance 47,671 F1: This transaction was made pursuant to a plan adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a plan adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
TELEFLEX INC
Report date May 15, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,716 |
Reported balance
After 2026-05-15 transaction · row 1
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 1,090 · Balance 3,716 F1: Restricted Stock Unit Award granted pursuant to the Teleflex Incorporated 2023 Stock Incentive Plan. Award vests 100% on the one-year anniversary of the grant date; provided, however, if the reporting person does not stand for re-election to the issuer's board of directors (the "Board") at the issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting"), the award will vest on the earlier of the one-year anniversary of the grant date and the date of the 2027 Annual Meeting, so long as such meeting is held at least 50 weeks after the issuer's 2026 annual meeting of stockholders (the "2026 Annual Meeting"). |
| Stock Option / (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $129.71 · Expires 2036-05-15 | Direct | 2,397 |
Reported balance
After 2026-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-15 · Grant · Acquired 2,397 · Balance 2,397 F2: Stock Option Award vests 100% on the one-year anniversary of the grant date; provided, however, if the reporting person does not stand for re-election to the Board at the 2027 Annual Meeting, the award will vest on the earlier of the one-year anniversary of the grant date and the date of the 2027 Annual Meeting, so long as such meeting is held at least 50 weeks after the 2026 Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Unit Award granted pursuant to the Teleflex Incorporated 2023 Stock Incentive Plan. Award vests 100% on the one-year anniversary of the grant date; provided, however, if the reporting person does not stand for re-election to the issuer's board of directors (the "Board") at the issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting"), the award will vest on the earlier of the one-year anniversary of the grant date and the date of the 2027 Annual Meeting, so long as such meeting is held at least 50 weeks after the issuer's 2026 annual meeting of stockholders (the "2026 Annual Meeting").
F2: Stock Option Award vests 100% on the one-year anniversary of the grant date; provided, however, if the reporting person does not stand for re-election to the Board at the 2027 Annual Meeting, the award will vest on the earlier of the one-year anniversary of the grant date and the date of the 2027 Annual Meeting, so long as such meeting is held at least 50 weeks after the 2026 Annual Meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2023 Filed May 11, 2023 21:51 UTC | TELEFLEX INC TFX · Entity 3798 | GrantStock Option / (Right to Buy) · Derivative | 1,076 | $0.00 Strike: $251.99 | $0.00 |
DisclosureSEC source: 0000096943-23-000066 · wf-form4_168384183762210.xml · derivative · entry 2 Patil Neena M · CIK 0001783908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,076 Underlying: Common Stock · 1,076 shares Expires 2033-05-09 Read SEC document |
| May 09, 2023 Filed May 11, 2023 21:51 UTC | TELEFLEX INC TFX · Entity 3798 | GrantCommon Stock | 527 | $0.00 | $0.00 |
DisclosureSEC source: 0000096943-23-000066 · wf-form4_168384183762210.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 926 F1 · kind: Restricted Stock Unit Award granted pursuant to the Teleflex Incorporated 2023 Stock Incentive Plan. Award vests on May 9, 2024. Read SEC document |
| March 05, 2023 Filed Mar 8, 2023 02:00 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,923 | $142.78 | $274,565.94 |
DisclosureSEC source: 0001765581-23-000021 · edgardoc.xml · nonDerivative · entry 2 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,339 F3 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 02:00 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 9,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-23-000021 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,262 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: Includes 74 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2022. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 21:23 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,510 | $142.34 | $499,613.40 |
DisclosureSEC source: 0001765581-22-000124 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,769 F1 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $142.28 to $142.50. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:15 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,321 | $153.72 | $203,064.12 |
DisclosureSEC source: 0001765581-22-000077 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,279 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 21:00 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,000 | $152.15 | $152,150.00 |
DisclosureSEC source: 0001765581-22-000059 · edgardoc.xml · nonDerivative · entry 2 Patil Neena M · CIK 0001783908 · Chief Legal Officer (CLO) 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,600 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · balance_after: Includes 84 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2022. Read SEC document |
| May 10, 2022 Filed Jun 8, 2022 21:00 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GiftOrdinary Shares | 161 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-22-000059 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · Chief Legal Officer (CLO) 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,516 F1 · kind: Charitable donation. Read SEC document |
| May 06, 2022 Filed May 10, 2022 21:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 296 | $153.92 | $45,559.20 |
DisclosureSEC source: 0001765581-22-000045 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,677 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.84 to $154.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 03, 2022 Filed May 5, 2022 13:56 UTC | TELEFLEX INC TFX · Entity 3798 | GrantStock Option / (Right to Buy) · Derivative | 1,937 | $0.00 Strike: $284.85 | $0.00 |
DisclosureSEC source: 0000096943-22-000063 · wf-form4_165175899480577.xml · derivative · entry 2 Patil Neena M · CIK 0001783908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,937 Underlying: Common Stock · 1,937 shares Expires 2032-05-03 F2 · derivative.exercise_date: Stock Option Award granted pursuant to Teleflex Incorporated 2014 Stock Incentive Plan. Award vests on November 3, 2022. Read SEC document |
| May 03, 2022 Filed May 5, 2022 13:56 UTC | TELEFLEX INC TFX · Entity 3798 | GrantCommon Stock | 399 | $0.00 | $0.00 |
DisclosureSEC source: 0000096943-22-000063 · wf-form4_165175899480577.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399 F1 · kind: Restricted Stock Unit Award granted pursuant to Teleflex Incorporated 2014 Stock Incentive Plan. Award vests on November 3, 2022. Read SEC document |
| March 05, 2022 Filed Mar 9, 2022 23:02 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,228 | $153.96 | $189,062.88 |
DisclosureSEC source: 0001765581-22-000024 · edgardoc.xml · nonDerivative · entry 2 Patil Neena M · CIK 0001783908 · Chief Legal Officer (CLO) and 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,973 F3 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 03, 2022 Filed Mar 9, 2022 23:02 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 8,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-22-000024 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · Chief Legal Officer (CLO) and 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,201 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2022, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: Includes 82 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2021. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 22:35 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 993 | $148.49 | $147,450.57 |
DisclosureSEC source: 0001765581-21-000094 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · CLO&SVP Legal and Corp Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,233 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 79 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 28, 2021. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:32 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 691 | $164.75 | $113,842.25 |
DisclosureSEC source: 0001765581-21-000038 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,147 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 23:07 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 7,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-21-000024 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · Chief Legal Officer (CLO) and 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2021, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: Includes 79 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 987 | $122.24 | $120,650.88 |
DisclosureSEC source: 0001765581-20-000063 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,489 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 76 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 29, 2020. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:42 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,125 | $0.00 Strike: $113.10 | $0.00 |
DisclosureSEC source: 0001765581-20-000024 · edgardoc.xml · derivative · entry 3 Patil Neena M · CIK 0001783908 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,125 Underlying: Ordinary Shares · 20,125 shares Expires 2030-02-26 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:42 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 875 | $0.00 Strike: $113.10 | $0.00 |
DisclosureSEC source: 0001765581-20-000024 · edgardoc.xml · derivative · entry 2 Patil Neena M · CIK 0001783908 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875 Underlying: Ordinary Shares · 875 shares Expires 2030-02-26 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:42 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 8,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-20-000024 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,400 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:01 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 27,084 | $0.00 Strike: $137.12 | $0.00 |
DisclosureSEC source: 0001765581-19-000058 · edgardoc.xml · derivative · entry 3 Patil Neena M · CIK 0001783908 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,084 Underlying: Ordinary Shares · 27,084 shares Expires 2029-08-07 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of July 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:01 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 2,916 | $0.00 Strike: $137.12 | $0.00 |
DisclosureSEC source: 0001765581-19-000058 · edgardoc.xml · derivative · entry 2 Patil Neena M · CIK 0001783908 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,916 Underlying: Ordinary Shares · 2,916 shares Expires 2029-08-07 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of July 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:01 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-19-000058 · edgardoc.xml · nonDerivative · entry 1 Patil Neena M · CIK 0001783908 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of August 5, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.